Roche/Genentech's IL-13 inhibiting investigational severe asthma product lebrikizumab has failed in one of its two pivotal trials, adding to reservations about its future. Lebrikizumab is already trailing other biological competitors to the market and the lack of robust data at Phase III could well spell the end in this indication.
Top-line data from the two identical placebo-controlled LAVOLTA studies show that LAVOLTA II missed the primary endpoint of a significant reduction in the rate of asthma exacerbations at 52 weeks in people with higher levels of serum periostin or blood eosinophils (both biomarkers of airway inflammation)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
